Journal
MOLECULAR PHARMACEUTICS
Volume 15, Issue 2, Pages 369-376Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00718
Keywords
polyamine biosynthesis; polyamine transport; pancreatic cancer; therapy; c-Myc
Funding
- Department of Defense Congressionally Directed Medical Research Program (CDMRP) Peer Review Cancer Research Program (PRCRP) Discovery Award [CA110724]
- CDMRP [545667, CA110724] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is highly chemo-resistant and has an extremely poor patient prognosis, with a survival rate at five years of <8%. There remains an urgent need for :innovative treatments. Targeting polyamine biosynthesis through. inhibition of ornithine decarboxylase with difluoromethylornithine (DFMO) has had mixed clinical success due to tumor escape via an undefined transport system, which imports exogenous polyamines and sustains intracellular polyamine pools. Here, we tested DFMO in combination with a pcilyamine transport inhibitor (PTI), Trimer44NMe, against Gemcitabine-resistant PDAC cells. DFMO alone and with Trimer44NMe significantly reduced PDAC cell viability by inducing apoptosis or diminishing proliferation. DFMO alone and with Trimer44NMe also inhibited in vivo orthotopic PDAC growth and resulted in decreased c-Myc expression, a readout of polyamine pathway dysfunction. Moreover, dual inhibition significantly prolonged survival of tumor-bearing mice. Collectively, these studies demonstrate that targeting polyamine biosynthesis and import pathways in PDAC can lead to increased survival in pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available